{"id":2732,"date":"2019-02-27T18:28:13","date_gmt":"2019-02-27T17:28:13","guid":{"rendered":"https:\/\/dewb.de\/en\/?p=2732"},"modified":"2019-02-28T10:31:35","modified_gmt":"2019-02-28T09:31:35","slug":"noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/","title":{"rendered":"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients"},"content":{"rendered":"<p><strong>Company aims to be ready to launch the trial in Q2-2019<\/strong><\/p>\n<p><strong>Berlin, Germany, February 27, 2019\u00a0<\/strong>&#8211; NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has filed the clinical trial application (CTA) with the Federal Institute for Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, BfArM), to start a Phase 1\/2 clinical trial combining NOX-A12 with radiotherapy to treat newly diagnosed brain cancer patients who would not benefit from the current standard of care and whose tumor cannot be fully resected by surgery.<\/p>\n<p>NOXXON plans to conduct the trial in collaboration with investigators at three hospitals in Germany: Mannheim, Essen and Bonn. The primary endpoint of this dose escalation study, which will assess up to three doses of NOX-A12, is the safety and tolerability of NOX-A12 combined with radiotherapy. Secondary endpoints include activity of the therapy, assessed through the monitoring of tumor vascularization by MRI scans, progression-free survival, overall survival and rates of response.<\/p>\n<p>\u201cProvided we can rapidly address any regulatory questions from the independent ethics committee, we should be ready to initiate the trial in mid-2019. The combination of NOX-A12 with radiation is the second therapeutic approach that we have developed for solid tumors and we believe that it can be applicable to many tumor types. We are encouraged by the strong support of clinical experts in both, the US and Europe,\u201d said Dr. Jarl Ulf Jungnelius, Chief Medical Officer of NOXXON Pharma.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2732\" data-postid=\"2732\" class=\"themify_builder_content themify_builder_content-2732 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>Company aims to be ready to launch this trial as second therapeutic approach developed for solid tumorse in Q2-2019<\/p>\n","protected":false},"author":3,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"Company aims to be ready to launch this trial as second therapeutic approach developed for solid tumorse in Q2-2019\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-27T17:28:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-28T09:31:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"marcoscheidler\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"marcoscheidler\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/\"},\"author\":{\"name\":\"marcoscheidler\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff\"},\"headline\":\"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients\",\"datePublished\":\"2019-02-27T17:28:13+00:00\",\"dateModified\":\"2019-02-28T09:31:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/\"},\"wordCount\":270,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/\",\"url\":\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/\",\"name\":\"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2019-02-27T17:28:13+00:00\",\"dateModified\":\"2019-02-28T09:31:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff\",\"name\":\"marcoscheidler\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g\",\"caption\":\"marcoscheidler\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"Company aims to be ready to launch this trial as second therapeutic approach developed for solid tumorse in Q2-2019","og_url":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2019-02-27T17:28:13+00:00","article_modified_time":"2019-02-28T09:31:35+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png","type":"image\/png"}],"author":"marcoscheidler","twitter_card":"summary_large_image","twitter_misc":{"Written by":"marcoscheidler","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/"},"author":{"name":"marcoscheidler","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff"},"headline":"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients","datePublished":"2019-02-27T17:28:13+00:00","dateModified":"2019-02-28T09:31:35+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/"},"wordCount":270,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/","url":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/","name":"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2019-02-27T17:28:13+00:00","dateModified":"2019-02-28T09:31:35+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/noxxon-files-application-for-phase-1-2-clinical-trial-combining-nox-a12-radiotherapy-for-the-treatment-of-brain-cancer-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON files application for phase 1\/2 clinical trial combining NOX-A12 &amp; radiotherapy for the treatment of brain cancer patients"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/69df13c3b5c68bc0094644a9b1e94eff","name":"marcoscheidler","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/33ec369bdcb31be9e19af5548b08ec5e?s=96&d=mm&r=g","caption":"marcoscheidler"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2732"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2732"}],"version-history":[{"count":2,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2732\/revisions"}],"predecessor-version":[{"id":2737,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2732\/revisions\/2737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}